JP2016521726A - 併用療法 - Google Patents
併用療法 Download PDFInfo
- Publication number
- JP2016521726A JP2016521726A JP2016518801A JP2016518801A JP2016521726A JP 2016521726 A JP2016521726 A JP 2016521726A JP 2016518801 A JP2016518801 A JP 2016518801A JP 2016518801 A JP2016518801 A JP 2016518801A JP 2016521726 A JP2016521726 A JP 2016521726A
- Authority
- JP
- Japan
- Prior art keywords
- phe
- thr
- trp
- lys
- cys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002648 combination therapy Methods 0.000 title description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 166
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 128
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 128
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims abstract description 117
- 102100020948 Growth hormone receptor Human genes 0.000 claims abstract description 115
- 239000000556 agonist Substances 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 88
- 108010068542 Somatotropin Receptors Proteins 0.000 claims abstract description 87
- 230000001965 increasing effect Effects 0.000 claims abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 102000005157 Somatostatin Human genes 0.000 claims description 97
- 108010056088 Somatostatin Proteins 0.000 claims description 97
- 229960000553 somatostatin Drugs 0.000 claims description 97
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 69
- 150000007523 nucleic acids Chemical class 0.000 claims description 69
- 102000039446 nucleic acids Human genes 0.000 claims description 68
- 108020004707 nucleic acids Proteins 0.000 claims description 68
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 47
- 206010000599 Acromegaly Diseases 0.000 claims description 31
- -1 aromatic amino acids Chemical class 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 108010033419 somatotropin-binding protein Proteins 0.000 claims description 26
- 230000014509 gene expression Effects 0.000 claims description 24
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 108020004705 Codon Proteins 0.000 claims description 23
- 235000000346 sugar Nutrition 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 22
- 230000000295 complement effect Effects 0.000 claims description 21
- 108091081024 Start codon Proteins 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 18
- 108020004414 DNA Proteins 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 230000008685 targeting Effects 0.000 claims description 16
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 14
- 239000002777 nucleoside Substances 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 9
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 229940104302 cytosine Drugs 0.000 claims description 7
- 230000014621 translational initiation Effects 0.000 claims description 7
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 6
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 6
- 125000003835 nucleoside group Chemical group 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 239000004055 small Interfering RNA Substances 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
- FHSGULRVYLHXFO-FFNFELIASA-N (3s,6s,9s,12r,15s,18s)-9-(4-aminobutyl)-3,15-dibenzyl-6-[(1r)-1-hydroxyethyl]-12-(1h-indol-3-ylmethyl)-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosane-2,5,8,11,14,17-hexone Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N1)=O)[C@H](O)C)C1=CC=CC=C1 FHSGULRVYLHXFO-FFNFELIASA-N 0.000 claims description 3
- NPJIOCBFOAHEDO-AVWFULIKSA-N (3s,6s,9s,12r,15s,18s)-9-(4-aminobutyl)-3-benzyl-15-[(4-hydroxyphenyl)methyl]-12-(1h-indol-3-ylmethyl)-1,18-dimethyl-6-propan-2-yl-1,4,7,10,13,16-hexazacyclooctadecane-2,5,8,11,14,17-hexone Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N(C)[C@@H](C)C(=O)N1)=O)C(C)C)C1=CC=C(O)C=C1 NPJIOCBFOAHEDO-AVWFULIKSA-N 0.000 claims description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 3
- UMJHAEUVYNEBNP-RXYCCRQDSA-N C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N1)=O)[C@H](O)C)C1=CC=C(O)C=C1 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N1)=O)[C@H](O)C)C1=CC=C(O)C=C1 UMJHAEUVYNEBNP-RXYCCRQDSA-N 0.000 claims description 3
- 108700026244 Open Reading Frames Proteins 0.000 claims description 3
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 3
- YYARMJSFDLIDFS-FKBYEOEOSA-N Pro-Phe-Trp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O YYARMJSFDLIDFS-FKBYEOEOSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 24
- 150000001875 compounds Chemical class 0.000 description 72
- 230000000692 anti-sense effect Effects 0.000 description 64
- 238000011282 treatment Methods 0.000 description 56
- 108010051696 Growth Hormone Proteins 0.000 description 45
- 102100038803 Somatotropin Human genes 0.000 description 45
- 239000000122 growth hormone Substances 0.000 description 45
- 108020004999 messenger RNA Proteins 0.000 description 43
- 239000000203 mixture Substances 0.000 description 38
- 210000002966 serum Anatomy 0.000 description 33
- 239000000074 antisense oligonucleotide Substances 0.000 description 25
- 238000012230 antisense oligonucleotides Methods 0.000 description 25
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 230000009467 reduction Effects 0.000 description 21
- 230000014616 translation Effects 0.000 description 21
- 108010016076 Octreotide Proteins 0.000 description 20
- 229960002437 lanreotide Drugs 0.000 description 20
- 229960002700 octreotide Drugs 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 238000013519 translation Methods 0.000 description 19
- XQEJFZYLWPSJOV-XJQYZYIXSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosa Chemical compound CC(O)=O.C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 XQEJFZYLWPSJOV-XJQYZYIXSA-N 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 18
- 230000003442 weekly effect Effects 0.000 description 18
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 16
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 108010021336 lanreotide Proteins 0.000 description 16
- 101150020003 GHR gene Proteins 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 238000009097 single-agent therapy Methods 0.000 description 13
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 101000632994 Homo sapiens Somatostatin Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 102000045305 human SST Human genes 0.000 description 11
- 239000011859 microparticle Substances 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 9
- 230000003285 pharmacodynamic effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 108050001286 Somatostatin Receptor Proteins 0.000 description 8
- 102000011096 Somatostatin receptor Human genes 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 238000011260 co-administration Methods 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 229940123051 Somatostatin receptor agonist Drugs 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 description 6
- 108700017947 pasireotide Proteins 0.000 description 6
- VMZMNAABQBOLAK-DBILLSOUSA-N pasireotide Chemical compound C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 VMZMNAABQBOLAK-DBILLSOUSA-N 0.000 description 6
- 229960005415 pasireotide Drugs 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 5
- 101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 description 5
- 230000002730 additional effect Effects 0.000 description 5
- 229960000643 adenine Drugs 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229940088679 drug related substance Drugs 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 108700037519 pegvisomant Proteins 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 229940099077 somavert Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical group 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 125000004437 phosphorous atom Chemical group 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 229940075620 somatostatin analogue Drugs 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 3
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108090000586 somatostatin receptor 2 Proteins 0.000 description 3
- 102000004052 somatostatin receptor 2 Human genes 0.000 description 3
- 108010082379 somatostatin receptor type 1 Proteins 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 2
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000006642 detritylation reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960005215 dichloroacetic acid Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 229960001494 octreotide acetate Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108700014314 sandostatinLAR Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000005987 sulfurization reaction Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- RZENOPCSYJWNKU-VIFPVBQESA-N (2s)-2-(aminomethylamino)-3-phenylpropanoic acid Chemical group NCN[C@H](C(O)=O)CC1=CC=CC=C1 RZENOPCSYJWNKU-VIFPVBQESA-N 0.000 description 1
- OLMICDUONLWRJA-ZETCQYMHSA-N (2s)-2-[amino(cyclohexyl)amino]propanoic acid Chemical compound OC(=O)[C@H](C)N(N)C1CCCCC1 OLMICDUONLWRJA-ZETCQYMHSA-N 0.000 description 1
- LKENCKKEVBCYAE-VIFPVBQESA-N (2s)-2-[butyl-(diaminomethylideneamino)amino]-6-(diaminomethylideneamino)hexanoic acid Chemical compound CCCCN(NC(N)=N)[C@H](C(O)=O)CCCCNC(N)=N LKENCKKEVBCYAE-VIFPVBQESA-N 0.000 description 1
- KZDNJQUJBMDHJW-VIFPVBQESA-N (2s)-2-amino-3-(5-bromo-1h-indol-3-yl)propanoic acid Chemical compound C1=C(Br)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 KZDNJQUJBMDHJW-VIFPVBQESA-N 0.000 description 1
- PDRJLZDUOULRHE-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-2-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=N1 PDRJLZDUOULRHE-ZETCQYMHSA-N 0.000 description 1
- XKDUODGOACYEEU-VIFPVBQESA-N (2s)-2-azaniumyl-3-(5-nitro-1h-indol-3-yl)propanoate Chemical compound C1=C([N+]([O-])=O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 XKDUODGOACYEEU-VIFPVBQESA-N 0.000 description 1
- DAMWHRWFABCBKR-VIFPVBQESA-N (2s)-6-[carbamimidoyl-(diaminomethylideneamino)amino]-2-(diethylamino)hexanoic acid Chemical compound CCN(CC)[C@H](C(O)=O)CCCCN(C(N)=N)NC(N)=N DAMWHRWFABCBKR-VIFPVBQESA-N 0.000 description 1
- ZODMYTRQCNEOFM-QMMMGPOBSA-N (2s)-6-amino-2-(propan-2-ylamino)hexanoic acid Chemical compound CC(C)N[C@H](C(O)=O)CCCCN ZODMYTRQCNEOFM-QMMMGPOBSA-N 0.000 description 1
- JIDDDPVQQUHACU-YFKPBYRVSA-N (2s)-pyrrolidine-2-carbaldehyde Chemical group O=C[C@@H]1CCCN1 JIDDDPVQQUHACU-YFKPBYRVSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical group C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 1
- UFSCXDAOCAIFOG-UHFFFAOYSA-N 1,10-dihydropyrimido[5,4-b][1,4]benzothiazin-2-one Chemical compound S1C2=CC=CC=C2N=C2C1=CNC(=O)N2 UFSCXDAOCAIFOG-UHFFFAOYSA-N 0.000 description 1
- PTFYZDMJTFMPQW-UHFFFAOYSA-N 1,10-dihydropyrimido[5,4-b][1,4]benzoxazin-2-one Chemical compound O1C2=CC=CC=C2N=C2C1=CNC(=O)N2 PTFYZDMJTFMPQW-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- AOTQGWFNFTVXNQ-UHFFFAOYSA-N 2-(1-adamantyl)acetic acid Chemical group C1C(C2)CC3CC2CC1(CC(=O)O)C3 AOTQGWFNFTVXNQ-UHFFFAOYSA-N 0.000 description 1
- QSHACTSJHMKXTE-UHFFFAOYSA-N 2-(2-aminopropyl)-7h-purin-6-amine Chemical compound CC(N)CC1=NC(N)=C2NC=NC2=N1 QSHACTSJHMKXTE-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
- BKQQPCDQZZTLSE-UHFFFAOYSA-N 2-amino-3-naphthalen-1-ylpropanoic acid;hydrochloride Chemical compound Cl.C1=CC=C2C(CC(N)C(O)=O)=CC=CC2=C1 BKQQPCDQZZTLSE-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- WKMPTBDYDNUJLF-UHFFFAOYSA-N 2-fluoroadenine Chemical compound NC1=NC(F)=NC2=C1N=CN2 WKMPTBDYDNUJLF-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- INPQIVHQSQUEAJ-UHFFFAOYSA-N 5-fluorotryptophan Chemical compound C1=C(F)C=C2C(CC(N)C(O)=O)=CNC2=C1 INPQIVHQSQUEAJ-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- NJBMMMJOXRZENQ-UHFFFAOYSA-N 6H-pyrrolo[2,3-f]quinoline Chemical compound c1cc2ccc3[nH]cccc3c2n1 NJBMMMJOXRZENQ-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 206010000159 Abnormal loss of weight Diseases 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical group CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 102000002494 Endoribonucleases Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000160765 Erebia ligea Species 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 101710099093 Growth hormone receptor Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 101100198353 Mus musculus Rnasel gene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101000633010 Rattus norvegicus Somatostatin Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- BHLMCOCHAVMHLD-REOHCLBHSA-N S-oxy-L-cysteine Chemical compound OC(=O)[C@@H](N)CS=O BHLMCOCHAVMHLD-REOHCLBHSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 102100029563 Somatostatin Human genes 0.000 description 1
- 101800004701 Somatostatin-28 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010042682 Swelling face Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- RLXCFCYWFYXTON-JTTSDREOSA-N [(3S,8S,9S,10R,13S,14S,17R)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-16-yl] N-hexylcarbamate Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC(=O)NCCCCCC)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 RLXCFCYWFYXTON-JTTSDREOSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000011292 agonist therapy Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004712 cancer cell adhesion Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 125000001369 canonical nucleoside group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical group C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- GTZOYNFRVVHLDZ-UHFFFAOYSA-N dodecane-1,1-diol Chemical group CCCCCCCCCCCC(O)O GTZOYNFRVVHLDZ-UHFFFAOYSA-N 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012731 long-acting form Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- ONTNXMBMXUNDBF-UHFFFAOYSA-N pentatriacontane-17,18,19-triol Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCCCCCC ONTNXMBMXUNDBF-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 150000002991 phenoxazines Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- RXTQGIIIYVEHBN-UHFFFAOYSA-N pyrimido[4,5-b]indol-2-one Chemical compound C1=CC=CC2=NC3=NC(=O)N=CC3=C21 RXTQGIIIYVEHBN-UHFFFAOYSA-N 0.000 description 1
- SRBUGYKMBLUTIS-UHFFFAOYSA-N pyrrolo[2,3-d]pyrimidin-2-one Chemical compound O=C1N=CC2=CC=NC2=N1 SRBUGYKMBLUTIS-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- IXGZXXBJSZISOO-UHFFFAOYSA-N s-(2-phenylacetyl)sulfanyl 2-phenylethanethioate Chemical compound C=1C=CC=CC=1CC(=O)SSC(=O)CC1=CC=CC=C1 IXGZXXBJSZISOO-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229940072272 sandostatin Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- GGYTXJNZMFRSLX-DFTNLTQTSA-N somatostatin-28 Chemical compound N([C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC1)C(O)=O)[C@@H](C)O)[C@@H](C)O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CO GGYTXJNZMFRSLX-DFTNLTQTSA-N 0.000 description 1
- NHXLMOGPVYXJNR-UHFFFAOYSA-N srif Chemical compound N1C(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)CNC(=O)C(C)N)CSSCC(C(O)=O)NC(=O)C(CO)NC(=O)C(C(O)C)NC(=O)C1CC1=CC=CC=C1 NHXLMOGPVYXJNR-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical group S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000013008 thixotropic agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
Abstract
Description
本出願は、2013年6月13日に出願された「併用療法」と題する米国特許出願第61/834,856号の優先権を主張するものである。該出願の全内容は、参照により本明細書に組み込まれる。
配列表は、2013年6月13日に作成された、423KBのサイズを有するテキストファイル、513110_ST25.txtとして本明細書と共に提供される。テキストファイルの内容は、その全体が参照により本明細書に組み込まれる。
A1は、Ala、Leu、Ile、Val、Nle、Thr、Ser、β-Nal、β-Pal、Trp、Phe、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、p-X-Phe、又はo-X-Pheの、D又はL異性体であり、
A2は、Ala、Leu、Ile、Val、Nle、Phe、β-Nal、ピリジル-Ala、Trp、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、o-X-Phe、又はp-X-Pheであり、
A3は、ピリジル-Ala、Trp、Phe、β-Nal、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、o-X-Phe、又はp-X-Pheであり、
A6は、Val、Ala、Leu、Ile、Nle、Thr、Abu、又はSerであり、
A7は、Ala、Leu、Ile、Val、Nle、Phe、β-Nal、ピリジル-Ala、Trp、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、o-X-Phe、又はp-X-Pheであり、
A8は、Ala、Leu、Ile、Val、Nle、Thr、Ser、Phe、β-Nal、ピリジル-Ala、Trp、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、p-X-Phe、又はo-X-Pheの、D又はL異性体であり、
Xはそれぞれ独立に、CH3、Cl、Br、F、OH、OCH3及びNO2からなる群から選択され、
各R1及びR2は、独立にH、低級アシル又は低級アルキルであり、R3はOH又はNH2であり、ただし、A1及びA8の少なくとも1つ並びにA2及びA7の少なくとも1つが芳香族アミノ酸でなければならず、更にA1、A2、A7及びA8の全てが芳香族アミノ酸であってはならない)
又はその薬学的に許容可能な塩である。
H-D-Phe-p-クロロ-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2;
H-D-Phe-p-NO2-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
H-D-Nal-p-クロロ-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH2;
H-D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
H-D-Phe-p-クロロ-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;若しくは
H-D-Phe-Ala-Tyr-D-Trp-Lys-Val-Ala-β-D-Nal-NH2;又は
その薬学的に許容可能な塩である。
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
D-β-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2;
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH2;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH;
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH;
Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH;
Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
Ac-D-Phe-Lys*-Tyr-D-Trp-Lys-Val-Asp-Thr-NH2(式中、アミド架橋はLys*とAspの間にある);
Ac-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(Et)2-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-H2;
Ac-L-hArg(Et)2-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;
Ac-L-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NHEt;
Ac-hArg(CH3,ヘキシル)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
H-hArg(ヘキシル)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;
Ac-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH2;
プロピオニル-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys(iPr)-Thr-Cys-Thr-NH2;
Ac-D-β-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg(Et)2-NH2;
Ac-D-Lys(iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH2;
Ac-D-hArg(Et)2-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH2;
Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH2;
Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH2;
Bmp-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH2;
H-ペンタフルオロ-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
Ac-D-β-Nal-Cys-ペンタフルオロ-Phe-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
H-D-Phe-Cys-β-Nal-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2;
シクロ(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe);
シクロ(Pro-Phe-D-Trp=Lys-Thr-N-Me-Phe);
シクロ(N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe);
シクロ(Pro-Tyr-D-Trp-Lys-Thr-Phe);
シクロ(Pro-Phe-D-Trp-Lys-Thr-Phe);
シクロ(Pro-Phe-L-Trp-Lys-Thr-Phe);
シクロ(Pro-Phe-D-Trp(F)-Lys-Thr-Phe);
シクロ(Pro-Phe-Trp(F)-Lys-Thr-Phe);
シクロ(Pro-Phe-D-Trp-Lys-Ser-Phe);
シクロ(Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe);
シクロ(D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe);
シクロ(D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe);
シクロ(D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe);
シクロ(D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr);
シクロ(Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe);
シクロ(Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe);
シクロ(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe);
シクロ(N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe);
シクロ(Pro-Tyr-D-Trp-4-Amphe-Thr-Phe);
シクロ(Pro-Phe-D-Trp-4-Amphe-Thr-Phe);
シクロ(N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba);
シクロ(Asn-Phe-D-Trp-Lys-Thr-Phe);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH(CH2)4CO);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-β-Ala);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH;
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe);
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe-Gly);
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly);
シクロ(Asn-Phe-Phe-D-Trp(F)-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp(NO2)-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-Trp(Br)-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe(I)-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr(But)-Gaba);
シクロ(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH;
シクロ(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys)-OH;
シクロ(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys)-OH;
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba);
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba;
シクロ(Phe-Phe-D-Trp(5F)-Lys-Thr-Phe-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys(Ac)-Thr-Phe-NH-(CH2)3-CO);
シクロ(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);若しくは
シクロ(Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);又は
その薬学的に許容可能な塩である。
D-β-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2;
H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH2;
その薬学的に許容可能な塩である。
D-Phe-シクロ(Cys-Phe-D-Trp-Lys-Thr-Cys)-Thr-ol又はその薬学的に許容可能な塩である。
配列番号1 - ソマトスタチンヌクレオチド配列
配列番号2 - ソマトスタチンポリペプチド配列
配列番号3 - オクトレオチドペプチド配列
配列番号4 - ヒト成長ホルモン受容体(hGHR) cDNA配列
配列番号5 - hGHR遺伝子配列
配列番号6〜83 - hGHRを標的とするオリゴヌクレオチド
配列番号84〜154 - hGHR標的配列
特に具体的に定義されない限り、本明細書で使用される全ての技術的及び科学的用語は、当業者により一般に理解されているのと同じ意味を有するととらえられるべきである(例えば、アンチセンス技術では、組換え技術、細胞培養、分子遺伝学、免疫学、免疫組織化学、タンパク質化学、及び生化学)。
β-Nal =β-ナフチルアラニン
β-Pal =β-ピリジルアラニン
hArg(Bu) = N-グアニジノ-(ブチル)-ホモアルギニン
hArg(Et)2 = N,N'-グアニジノ-(ジエチル)-ホモアルギニン
hArg(CH2CF3) 2 = N,N'-グアニジノ-bis-(2,2,2,-トリフルオロエチル)-ホモアルギニン
hArg(CH3, ヘキシル) = N,N'-グアニジノ-(メチル, ヘキシル)-ホモアルギニン
Lys(Me) = NE-メチルリシン
Lys(iPr) = N-イソプロピルリシン
AmPhe =アミノメチルフェニルアラニン
AchxAla =アミノシクロヘキシルアラニン
Abu =α-アミノ酪酸
Tpo = 4-チアプロリン
MeLeu = N-メチルロイシン
Orn =オルニチン
Nle =ノルロイシン
Nva =ノルバリン
Trp(Br) = 5-ブロモ-トリプトファン
Trp(F) = 5-フルオロ-トリプトファン
Trp(NO2) = 5-ニトロ-トリプトファン
Gaba =γ-アミノ酪酸
Bmp =β-メルカプトプロピオニル
Ac =アセチル
Pen =ペニシラミン
本発明は、インスリン様成長因子I(IGF-I)に起因する、及び/又はインスリン様成長因子I(IGF-I)のレベルの増加に関連する疾患、障害、又は状態の予防及び/又は治療に有用な方法を提供する。本明細書で使用されるとき、用語「治療」は、疾患、障害、又は状態の変化又は改善をもたらすために医薬組成物を投与することを指す。本明細書で使用されるとき、用語「予防」は、疾患、障害、又は状態の少なくとも1つの症状の発生を停止又は妨げるために医薬組成物を投与することを指す。治療の対象とされる対象は、哺乳動物、好ましくはヒトである。本明細書で使用されるとき、「インスリン様成長因子Iのレベルの増加(IGF-I)」は、年齢及び性別で補正された正常範囲を超える又は正常範囲中(例えば正常範囲の上限)のレベルを含む。
ソマトスタチン(成長ホルモン放出抑制因子又はSRIF)は、14アミノ酸アイソフォーム(ソマトスタチン-14)及び28アミノ酸アイソフォーム(ソマトスタチン-28)の両方を有する[Wilson, J.及びFoster, D.、Williams Textbook of Endocrinology、510頁(第7版、1985)参照のこと]。該化合物は成長ホルモンの分泌の阻害剤であり、もともと視床下部から単離された(Brazeauら、1973)。天然のソマトスタチンは、エンドペプチダーゼ及びエキソペプチダーゼにより急速に不活性化されるため、インビボで極めて短い作用持続時間を有する。このホルモンの作用持続時間、生物学的活性、及び選択性(例えば、特定のソマトスタチン受容体に対する)を増大させるために、多くの新規の類似体が調製されている。このような類似体は、本明細書では「ソマトスタチンアゴニスト」と呼ばれるであろう。更に、ソマトスタチン受容体に結合する、有機部分により修飾された短いペプチド、及び当技術分野で認識されているアミノ酸を構造の一部として持たない有機分子などの非ペプチドである化合物も、「ソマトスタチンアゴニスト」の意味の範囲内である。
EP出願第25 164 EU号;
Van Binstら Peptide Research (1992) 5:8;
Horvath, A.ら Abstract、「Conformations of Somatostatin Analogs Having Antitumor Activity」、22nd European peptide Symposium、1992年9月13〜19日、Interlaken、Switzerland;
PCT出願WO 91/09056 (1991);
EP出願0 363 589 A2号(1990);
米国特許第4,904,642号(1990);
米国特許第4,871,717号(1989);
米国特許第4,853,371号(1989);
米国特許第4,725,577号(1988);
米国特許第4,684,620号(1987)
米国特許第4,650,787号(1987);
米国特許第4,603,120号(1986);
米国特許第4,585,755号(1986);
EP出願第0 203 031 A2号(1986);
米国特許第4,522,813号(1985);
米国特許第486,415号(1984);
米国特許第4,485,101号(1984);
米国特許第4,435,385号(1984);
米国特許第4,395,403号(1983);
米国特許第4,369,179号(1983);
米国特許第4,360,516号(1982);
米国特許第4,358,439号(1982);
米国特許第4,328,214号(1982);
米国特許第4,316,890号(1982);
米国特許第4,310,518号(1982);
米国特許第4,291,022号(1981);
米国特許第4,238,481号(1980);
米国特許第4,235,886号(1980);
米国特許第4,224,190号(1980);
米国特許第4,211,693号(1980);
米国特許第4,190,648号(1980);
米国特許第4,146,612号(1979);及び
米国特許第4,133,782号(1979)。
D-β-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2;
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
D-β-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2;
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH2;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH;
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH;
Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH;
Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
Ac-D-Phe-Lys*-Tyr-D-Trp-Lys-Val-Asp-Thr-NH2(式中、アミド架橋はLys*とAspの間に形成されている);
Ac-hArg(Et)2Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(BU)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(Et)2-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-L-hArg(Et)2-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;
Ac-L-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NHEt;
Ac-hArg(CH3,ヘキシル)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
H-hArg(ヘキシル)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;
Ac-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH2;
プロピオニル-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys(iPr)-Thr-Cys-Thr-NH2;
Ac-D-β-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg(Et)2-NH2;
Ac-D-Lys(iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH2;
Ac-D-hArg(Et)2-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH2;
Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH2;
Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH2;
Bmp-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH2;
H-ペンタフルオロ-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
Ac-D-β-Nal-Cys-ペンタフルオロ-Phe-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
H-D-Phe-Cys-β-Nal-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2;
シクロ(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe);
シクロ(Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe);
シクロ(N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe);
シクロ(Pro-Tyr-D-Trp-Lys-Thr-Phe);
シクロ(Pro-Phe-D-Trp-Lys-Thr-Phe);
シクロ(Pro-Phe-L-Trp-Lys-Thr-Phe);
シクロ(Pro-Phe-D-Trp(F)-Lys-Thr-Phe);
シクロ(Pro-Phe-D-Trp-Lys-Ser-Phe);
シクロ(Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe);
シクロ(D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe);
シクロ(D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe);
シクロ(D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe);
シクロ(D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr);
シクロ(Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe);
シクロ(Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe);
シクロ(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe);
シクロ(N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe);
シクロ(Pro-Tyr-D-Trp-4-Amphe-Thr-Phe);
シクロ(Pro-Phe-D-Trp-4-Amphe-Thr-Phe);
シクロ(N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba);
シクロ(Asn-Phe-D-Trp-Lys-Thr-Phe);
シクロ(Asn-Phe-D-Trp-Lys-Thr-Lys-Thr-Phe-NH(CH2)4CO);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-β-Ala;
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH;
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe);
シクロPhe-Phe-D-Trp-Lys-Thr-Phe-Gly);
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly);
シクロ(Asn-Phe-Phe-D-Trp(F)-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp(NO2)-Lys-Thr-Phe-Gaba)
シクロ(Asn-Phe-Phe-Trp(Br)-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe(I)-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr(But)-Gaba);
シクロ(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH;
シクロ(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys)-OH;
シクロ(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys)-OH;
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba);
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba);
シクロ(Phe-Phe-D-Trp(5F)-Lys-Thr-Phe-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys(Ac)-Thr-Phe-NH-(CH2)3-CO);
シクロ(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
シクロ(Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);及び
H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH2。
A1は、Ala、Leu、Ile、Val、Nle、Thr、Ser、β-Nal、β-Pal、Trp、Phe、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、p-X-Phe、又はo-X-Pheの、D又はL異性体であり、
A2は、Ala、Leu、Ile、Val、Nle、Phe、β-Nal、ピリジル-Ala、Trp、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、o-X-Phe、又はp-X-Pheであり、
A3は、ピリジル-Ala、Trp、Phe、β-Nal、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、o-X-Phe、又はp-X-Pheであり、
A6は、Val、Ala、Leu、Ile、Nle、Thr、Abu、又はSerであり、
A7は、Ala、Leu、Ile、Val、Nle、Phe、β-Nal、ピリジル-Ala、Trp、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、o-X-Phe、又はp-X-Pheであり、
A8は、Ala、Leu、Ile、Val、Nle、Thr、Ser、Phe、β-Nal、ピリジル-Ala、Trp、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、p-X-Phe、又はo-X-Pheの、D又はL異性体であり、
Xはそれぞれ独立に、CH3、Cl、Br、F、OH、OCH3及びNO2からなる群から選択され、
各R1及びR2は、独立にH、低級アシル又は低級アルキルであり、R3はOH又はNH2であり、ただし、A1及びA8の少なくとも1つ並びにA2及びA7の少なくとも1つが芳香族アミノ酸でなければならず、更にA1、A2、A7及びA8の全てが芳香族アミノ酸であってはならない)。
H-D-Phe-p-クロロ-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2;
H-D-Phe-p-NO2-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
H-D-Nal-p-クロロ-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH2;
H-D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
H-D-Phe-p-クロロ-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;及び
H-D-Phe-Ala-Tyr-D-Trp-Lys-Val-Val-Ala-β-D-Nal-NH2;又は
その薬学的に許容可能な塩が含まれる。
ソマトスタチンアゴニストを合成する方法は、例えば、上記に引用された米国特許及び他の参考文献で例証されているように、十分に文書化されており当業者の能力の範囲内である。
本開示の方法において有用なソマトスタチンアゴニストは、1つ又は複数の化学基に共有結合(以下「コンジュゲート」)することができる。このようなコンジュゲーションは、非修飾ソマトスタチンアゴニストより大きい実際の分子量を有するソマトスタチンアゴニストコンジュゲートをもたらす。
本開示の方法は、成長ホルモン(GH)シグナル伝達又はGH/インスリン様成長因子-I(IGF-I)軸、特にGHR及び/若しくはIGF-Iの発現を調節するための、成長ホルモン受容体(GHR)に対するアンチセンス化合物の使用に依拠する。好ましくは、アンチセンス化合物はオリゴヌクレオチドである。しかし、オリゴヌクレオチド模倣体を含むがこれに限定されない他のオリゴマーアンチセンス化合物が企図される。
本開示は、成長ホルモン受容体(GHR)の発現を阻害するアンチセンスオリゴヌクレオチドの使用を提供する。
本開示の方法において有用なアンチセンス化合物には、修飾骨格又は非天然ヌクレオシド間結合を有するオリゴヌクレオチドが含まれる。修飾骨格を有するオリゴヌクレオチドには、骨格中にリン原子を保持するもの、及び骨格中にリン原子を持たないものが含まれる。
本開示の方法において有用なアンチセンス化合物には、ヌクレオチド単位の糖及びヌクレオシド間結合の両方(すなわち骨格)が、新規の基と置き換えられるオリゴヌクレオチド模倣体が含まれる。核酸塩基単位は、標的核酸とのハイブリダイゼーションのために維持される。
本開示の方法において有用なアンチセンス化合物には、1つ又は複数の置換された糖部分を有するオリゴヌクレオチドが含まれる。
本開示の方法において有用なアンチセンス化合物には、核酸塩基修飾又は置換を有するオリゴヌクレオチドが含まれる。本明細書で使用されるとき、「非修飾」又は「天然」核酸塩基には、プリン塩基アデニン(A)及びグアニン(G)、並びにピリミジン塩基チミン(T)、シトシン(C)、及びウラシル(U)が含まれる。
本開示の方法において有用なアンチセンス化合物は、アンチセンス化合物の活性、細胞分布又は細胞取り込みを増大させる1つ若しくは複数の部分又は基にコンジュゲートされてもよい。
当業者により理解されるように、所与の化合物中の全ての位置が均一に修飾される必要はなく、実際に、1つを超える上述の修飾が、単一オリゴヌクレオチド、又はオリゴヌクレオチド内の単一ヌクレオシドにすら組み込まれてもよい。
1つの実施形態においてアンチセンス化合物は、GHR mRNAにハイブリダイズするように設計された第2世代ホスホロチオエート骨格2'-MOE-修飾キメラオリゴヌクレオチドギャップマーである。
固相合成の各サイクルは、支持体結合オリゴヌクレオチドの5'末端ヌクレオシドの酸不安定性5'-O-4,4'-ジメトキシトリチル(DMT)保護基の除去で開始する。これは、酸性溶液[例えば、トルエン中ジクロロ酢酸(DCA)]による処理により達成される。脱トリチル化後、過剰な試薬は、次の反応のための準備においてアセトニトリルで洗浄して支持体から除去される。
鎖伸長は、活性化因子(例えば、1H-テトラゾール)の存在下、支持体結合オリゴヌクレオチドの5'-ヒドロキシル基と、この特定の塩基位置に対応するホスホラミダイト溶液(例えば、塩基2に対して: MOE-MeCアミダイト)との反応により達成される。これは、入ってくるヌクレオチドシントンと支持体結合オリゴヌクレオチド鎖の間に亜リン酸トリエステル結合の形成をもたらす。カップリング反応後、過剰な試薬は、次の反応のための準備においてアセトニトリルで洗浄して支持体から除去される。
新たに形成された亜リン酸トリエステル結合は、硫黄転移試薬(例えば、フェニルアセチルジスルフィド)の溶液で処理して、対応する(O,O,O)-トリアルキルホスホロチオエートトリエステルに変換される。硫化後、過剰な試薬は、次の反応のための準備においてアセトニトリルで洗浄して支持体から除去される。
任意の所与のサイクルで利用可能なごく一部の5'-ヒドロキシ基は、伸長しない。この後のサイクルのいずれかにおけるこれらの基のカップリングは、所望の生成物から分離するのが難しいプロセス関連不純物(「DMT-オン(n-1)-mer」)の形成をもたらすことになる。これらの不純物の形成を防ぎ精製を促進するために、「キャッピング試薬」(例えば、無水酢酸及びN-メチルイミダゾール/アセトニトリル/ピリジン)が反応容器に導入されてキャップ配列を提供する。得られた失敗配列(failure sequence) [「DMT-オフショートマー(shortmer)」]は、逆相HPLC精製により所望の生成物から分離される。キャッピング反応後、過剰な試薬は、次の反応のための準備においてアセトニトリルで洗浄して支持体から除去される。
プロセスのアセンブリ部分の完了後、(O,O,O)-トリアルキルホスホロチオエートトリエステルヌクレオチド間結合を保護するシアノエチル基が、アセトニトリル中トリエチルアミン(TEA)溶液で処理して除去される。この工程中に生成された試薬及びアクリロニトリルは、アセトニトリルでカラムを洗浄して除去される。
環外アミノ基の脱保護及び支持体からの粗生成物の切断は、水性水酸化アンモニウムとのインキュベーションにより達成される(反応f)。粗い5'-O-DMT保護生成物の精製は、逆相HPLCにより達成される。逆相HPLC工程は、DMT-オフ失敗配列を除去する。溶出プロファイルは、UV吸収分光法によりモニタリングされる。DMT-オンオリゴヌクレオチド生成物を含有する画分が回収され、分析される。
5'-O-DMT保護オリゴヌクレオチドを含有する逆相HPLC画分がプールされ、沈殿タンクに移される。幾つかの合成の精製から得られた生成物が、プロセスのこの段階で混合される。5'末端に付加されたDMT基を除去するために、精製DMT-オンオリゴヌクレオチドが酸(例えば、酢酸)で処理される。所定の時間の酸曝露及び中和後、オリゴヌクレオチド原薬は単離され、乾燥される。
特定の核酸に対するアンチセンス化合物の「標的化」は、多段階プロセスとなり得る。プロセスは通常、機能が調節される標的核酸の同定で始まる。本開示において、標的核酸は、成長ホルモン受容体(GHR)をコードする。用語「標的核酸」は、GHRをコードするDNA、このようなDNAから転写されるRNA (プレmRNA及びmRNA又はこれらの部分を含む)、及び更に、このようなRNAから得られるcDNAを包含する。
例示的な標的配列は表2に示されている。
本開示の方法において有用なアンチセンス化合物は、他の分子、分子構造、又は化合物の混合物と混合され、カプセル化され、コンジュゲートされ、又はさもなければ結合され得、取り込み、分布及び/又は吸収を補助するための、例えば、リポソーム、受容体標的化分子、経口、直腸、局所又は他の製剤をもたらす。
本開示の方法は、対象におけるインスリン様成長因子I(IGF-I)レベルを低減するために、ソマトスタチン受容体アゴニスト活性を有するソマトスタチン類似体を、成長ホルモン受容体(GHR)を標的とするオリゴヌクレオチドと併用することの予想外の追加の活性及び/又は相乗効果に依拠する。
フェーズI試験の主な目的は、ATL1103の安全性、忍容性及び薬物動態(pK)を評価することであった。
背景及び試験デザイン
・正常なメスのマウス(1群当たりN=8)に生理食塩水、ATL1103 (2用量)、ソマバート(2用量)、及びオクトレオチド酢酸塩(1用量)を3週間注射し、単独で使用した場合(単独療法)、及びATL1103と併用して使用した場合を評価した。
・血清IGF-I値を3週間にわたり毎週モニターし、相対的肝臓GHR RNA及びIGF-I RNAレベルを投与3週目で決定した。
・ソマバート及びオクトレオチドは先端巨大症に対する現在の薬物療法であり、このマウス試験で使用された用量は、先行発表された齧歯類試験において活性であることが以前に示されている。
・この試験で使用されたより高用量のATL1103は、3週目で活性となり、3週目でGHr RNA及び血清IGF-Iを低減することが以前にマウスで示されている。
・正常なマウスでは肝臓は血液中のIGF-Iの主な供給源であり、血清IGF-Iの約70%に寄与する。
・GHr及びIGF-I RNAデータは一元配置ANOVAを用いて統計的に分析し、これに続いて治療群を生理食塩水対照と比較した場合のダネット検定を行った。sIGF-Iデータは、一元配置ANOVA及びペアワイズ比較を用いて統計的に分析した。
・該試験の目的は、併用治療の潜在的臨床効果のガイドとして、単独療法対併用アプローチ(他の既存の治療と併用したATL1103)の効果をマウスで評価することであった。
・ATL1103 (25mg/kg、週2回)は、生理食塩水対照と比べて、3週目で肝臓GHr RNA (99.7%、p=0.001)、IGF-I RNA (76.2%、p=0.001)、及び血清IGF-I (44.5%、p=0.003)を低減し、対照生理食塩水と比べて1週目(36.5%、p=0.0070)及び2週目(41.5%、p=0.004)時点で類似のsIGF-I低減が見られた。
・より低用量のATL1103 (12mg/kg、第1週は3回、次いで2週間は週2回)は、3週目で肝臓GHr RNA (99%、p=0.001)、IGF-I RNA (64.3%、p=0.001)を低減する。
・オクトレオチド(1.25mg/kg、1日2回)は、生理食塩水対照と比べて、3週目で肝臓GHr RNA (82.9%、p=0.001)、IGF-I RNA(47.7%、p=0.05)、及び血清IGF-I(25.2%、p=0.03)を低減し、早ければ1週目に類似のsIGF-I低減が見られた(25.1%、p=0.012)。
・ATL1103は、この試験で使用された用量でオクトレオチドにより達成されるレベルより低いレベルまで肝臓GHr RNA及びIGF-I RNAを低減する。
・ソマバート(20mg/kg、1日おき)は、生理食塩水対照と比べて3週目で肝臓GHr RNA (79.9%、p=0.01)及びIGF-I RNA (43.2%、p=0.05)を低減した。(注意: sIGF-Iアッセイは、ソマバート治療標本におけるsIGF-Iレベルを、より高いソマバート用量では1週目で>2倍の増加を示すと評価した。ソマバートはこの試験においてsIGF-Iを減少させることが予測され、これはアッセイに問題があったことを示唆するものであり、そのためソマバートに関する他のsIGF-Iデータはここでは報告されていない)。より低量(5mg/kg、1日おき)のソマバートは、肝臓GHr RNA (23%、p=0.05)を増加させ、生理食塩水対照と比べて肝臓IGF-I RNAに対する効果はなかった。
・ATL1103は、この試験で使用された高用量のソマバートで達成されるレベルより低いレベルまで肝臓GHr RNA及びIGF-I RNAレベルを低減する。
・オクトレオチド(1.25mg/kg、1日2回)とのATL1103 (25mg/kg、週2回)併用は、3週目で生理食塩水対照と比べて、GHr RNA(99.5%、p=0.001)、IGF-I RNA (76%、p=0.001)、及びsIGF-I (42.3%、p=0.005)を著しく低減した。
・オクトレオチドとのATL1103併用は、オクトレオチド単独療法と比べてこれらのパラメーターごとにより大きな活性を示した。併用は、このマウス試験では3週目でATL1103単独療法と比べて追加の活性を示さなかった。
・1週目のオクトレオチド(1.25mg/kg 1日2回)とのATL1103 (25mg/kg、週2回)併用は、ベースライン対照レベルと比べてsIGF-I (44%、p<0.002)の著しい低減を示した。1週目のATL1103 (25mg/kg、週2回)単独療法は、ベースライン対照レベルと比べてsIGF-Iの低減 (25%、p<0.013)を示し、オクトレオチド(1.25mg/kg、1日2回)は、ベースライン対照レベルと比べてsIGF-Iを低減した(15%、p<0.04)。
・第1週においてオクトレオチドとのATL1103併用は、ATL1103がオクトレオチドのsIGF-I低減を更に低減することが著しく可能であり、オクトレオチドはテストした単回投与でATL1103のsIGF-I低減を更に低減できることを示した。これは、併用が単独療法と比べて追加の効果を有することを示した。
・高い活性用量ソマバートとのATL1103低用量の併用は、3週目で生理食塩水と比べて肝臓GHr RNA (99.5%、p=0.001)、肝臓IGF-I RNA (86.6%、p=0.001)を低減した。ソマバートとのATL1103高用量の併用は、3週目で対照生理食塩水と比べて肝臓GHr RNA (99.8%、p=0.001)、IGF-I RNA (87.6%、p=0.001)を低減した。
・活性なより高用量ソマバート(20mg/kg、1日おき)とのATL1103 (より低用量及びより高用量)併用は3週目で、ATL1103又はソマバート単独療法のどちらかと比べて統計的に有意な更なる肝臓IGF-I RNA低減を示した。これは、因子構造統計分析及びt検定を用いて観察された。t検定を用いた肝臓GHr RNAのレベルにおいて統計的に有意な更なる低減もあった。
ATL1103は、1日当たり250mg、3週にわたって1、3、5、7、14及び21日目に6回、又は250mg、21日間で週2回、並びに更に5週間、250mgで週1回又は2回で皮下的に投与する。サンドスタチン-LARは、同じ8週期間にわたって28日ごとに20mgで投与する。
最大15名の先端巨大症の群はサンドスタチン-LAR用量で維持し、実施例1に記載されているようにATL1103を追加投与する。
15名の先端巨大症の群は、ATL1103と同じ日に、(i) 90mg、28日ごとに1回、ランレオチド-LAR用量、又は(ii) 120mg、28日ごとに1回、ランレオチド-LARを既に投与された患者に、200mg ATL1103、13週間週1回又は2回投与で投与する。
糖尿病性網膜症を有する15名の患者の群は、200mg ATL1103、13週間週1回又は2回投与、及び13週間、ATL1103と同じ日に(i) 20mg、28日ごとに1回、オクトレオチド-LAR、又は(ii) 30mg、28日ごとに1回、オクトレオチド-LARのどちらかを投与する。
IGF-Iの増加に関連する癌を有する15名の患者の群に、200mg ATL1103、13週間、週1回又は2回投与、及び13週間、(i) 90mg、28日ごとに1回、ランレオチド-LAR、又は(ii) 120mg、28日ごとに1回、ランレオチド-LARのどちらかを投与する。
ソマトスタチン類似体を、先端巨大症患者が現在治療に用いている用量、例えば20、30、mg/28日若しくはこれを超えるオクトレオチド-LAR、又は90、120mg/28日、ランレオチド-LAR、又は40から60mgパシレオチド-LARで投与する。
ソマトスタチン類似体を、先端巨大症患者が現在治療に用いている、例えば上記の実施例に概説されているような用量で、皮下的に又は筋肉内に投与する。
ソマトスタチン類似体を、先端巨大症患者が現在治療に用いている、例えば上記の実施例に概説されているような用量で、皮下的に又は筋肉内に投与する。
ATL1103のフェーズII試験は、13週間(3カ月) ATL1103で投与し、2カ月間追跡調査した24名の成人先端巨大症患者におけるATL1103での2つの皮下投与計画の安全性、忍容性、薬物動態及び有効性のランダム化、オープンラベル、並行群間試験である。2つのATL1103投与計画、(a) 200mg、第1週に3回、次いでその後は週1回(200mg/週)、又は(b) 200mg、第1週に3回、次いでその後は週2回(400mg/週)をテストした。該試験の主要評価項目又は主な目的は、(i)先端巨大症患者におけるATL1103の安全性及び忍容性を評価すること、並びに(ii)先端巨大症患者における皮下経路を介したATL1103の単回投与及び複数回投与薬物動態プロフィールを評価することであった。試験プロトコルにもある副次的だが重要な評価項目は、患者における血清インスリン様成長因子I(IGF-I)レベルに対するATL1103の効果の評価であった。副次的評価項目は、フェーズII試験で使用される2つの投与計画ごとにベースラインレベルと比べた、治療終了時の血清IGF-Iレベル低減の平均パーセンテージであった。
Claims (35)
- インスリン様成長因子I(IGF-I)に起因及び/又は関連する疾患を治療又は予防する方法であって、それを必要とする対象に、成長ホルモン受容体(GHR)の発現が阻害されるようにGHRをコードする核酸を標的とする8から80核酸塩基長のオリゴヌクレオチドと併用して、ソマトスタチンアゴニストを投与する工程を含み、これにより前記対象におけるIGF-Iのレベルを低減する、方法。
- 前記疾患が、先端巨大症、巨人症、糖尿病性網膜症、糖尿病性腎症、又は前立腺癌、骨髄腫、肺癌、乳癌、若しくは結腸癌などのIGF-I陽性癌である、請求項1に記載の方法。
- 対象におけるインスリン様成長因子I(IGF-I)のレベルを低減する方法であって、成長ホルモン受容体(GHR)の発現が阻害されるようにGHRをコードする核酸を標的とする8から80核酸塩基長のオリゴヌクレオチドと併用して、ソマトスタチンアゴニストを投与する工程を含み、これにより前記対象におけるIGF-Iのレベルを低減する、方法。
- 前記ソマトスタチンアゴニストが、
A1は、Ala、Leu、Ile、Val、Nle、Thr、Ser、β-Nal、β-Pal、Trp、Phe、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、p-X-Phe、又はo-X-Pheの、D又はL異性体であり、
A2は、Ala、Leu、Ile、Val、Nle、Phe、β-Nal、ピリジル-Ala、Trp、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、o-X-Phe、又はp-X-Pheであり、
A3は、ピリジル-Ala、Trp、Phe、β-Nal、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、o-X-Phe、又はp-X-Pheであり、
A6は、Val、Ala、Leu、Ile、Nle、Thr、Abu、又はSerであり、
A7は、Ala、Leu、Ile、Val、Nle、Phe、β-Nal、ピリジル-Ala、Trp、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、o-X-Phe、又はp-X-Pheであり、
A8は、Ala、Leu、Ile、Val、Nle、Thr、Ser、Phe、β-Nal、ピリジル-Ala、Trp、2,4-ジクロロ-Phe、ペンタフルオロ-Phe、p-X-Phe、又はo-X-Pheの、D又はL異性体であり、
Xはそれぞれ独立に、CH3、Cl、Br、F、OH、OCH3及びNO2からなる群から選択され、
各R1及びR2は、独立にH、低級アシル又は低級アルキルであり、R3はOH又はNH2であり、ただし、A1及びA8の少なくとも1つ並びにA2及びA7の少なくとも1つが芳香族アミノ酸でなければならず、更にA1、A2、A7及びA8の全てが芳香族アミノ酸であってはならない)
又はその薬学的に許容可能な塩である、請求項1から3のいずれか一項に記載の方法。 - 前記ソマトスタチンアゴニストが、
H-D-Phe-p-クロロ-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2;
H-D-Phe-p-NO2-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
H-D-Nal-p-クロロ-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH2;
H-D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
H-D-Phe-p-クロロ-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;若しくは
H-D-Phe-Ala-Tyr-D-Trp-Lys-Val-Ala-β-D-Nal-NH2;又は
その薬学的に許容可能な塩である、請求項1から3のいずれか一項に記載の方法。 - 前記ソマトスタチンアゴニストが、
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
D-β-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2;
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH2;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH;
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH;
Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH;
Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
Ac-D-Phe-Lys*-Tyr-D-Trp-Lys-Val-Asp-Thr-NH2(式中、アミド架橋はLys*とAspの間にある);
Ac-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(Et)2-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-H2;
Ac-L-hArg(Et)2-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;
Ac-L-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NHEt;
Ac-hArg(CH3、ヘキシル)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
H-hArg(ヘキシル)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;
Ac-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH2;
プロピオニル-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys(iPr)-Thr-Cys-Thr-NH2;
Ac-D-β-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg(Et)2-NH2;
Ac-D-Lys(iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-D-hArg(CH2CF3)2-D-hArg(CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH2;
Ac-D-hArg(Et)2-D-hArg(Et)2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;
Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH2;
Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH2;
Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH2;
Bmp-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH2;
H-ペンタフルオロ-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
Ac-D-β-Nal-Cys-ペンタフルオロ-Phe-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
H-D-Phe-Cys-β-Nal-D-Trp-Lys-Val-Cys-Thr-NH2;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2;
シクロ(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe);
シクロ(Pro-Phe-D-Trp=Lys-Thr-N-Me-Phe);
シクロ(N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe);
シクロ(Pro-Tyr-D-Trp-Lys-Thr-Phe);
シクロ(Pro-Phe-D-Trp-Lys-Thr-Phe);
シクロ(Pro-Phe-L-Trp-Lys-Thr-Phe);
シクロ(Pro-Phe-D-Trp(F)-Lys-Thr-Phe);
シクロ(Pro-Phe-Trp(F)-Lys-Thr-Phe);
シクロ(Pro-Phe-D-Trp-Lys-Ser-Phe);
シクロ(Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe);
シクロ(D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe);
シクロ(D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe);
シクロ(D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe);
シクロ(D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr);
シクロ(Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe);
シクロ(Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe);
シクロ(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe);
シクロ(N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe);
シクロ(Pro-Tyr-D-Trp-4-Amphe-Thr-Phe);
シクロ(Pro-Phe-D-Trp-4-Amphe-Thr-Phe);
シクロ(N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba);
シクロ(Asn-Phe-D-Trp-Lys-Thr-Phe);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH(CH2)4CO);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-β-Ala);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH;
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe);
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe-Gly);
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly);
シクロ(Asn-Phe-Phe-D-Trp(F)-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp(NO2)-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-Trp(Br)-Lys-Thr-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe(I)-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr(But)-Gaba);
シクロ(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH;
シクロ(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys)-OH;
シクロ(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys)-OH;
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba);
シクロ(Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba;
シクロ(Phe-Phe-D-Trp(5F)-Lys-Thr-Phe-Phe-Gaba);
シクロ(Asn-Phe-Phe-D-Trp-Lys(Ac)-Thr-Phe-NH-(CH2)3-CO);
シクロ(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);若しくは
シクロ(Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);又は
その薬学的に許容可能な塩である、請求項1から3のいずれか一項に記載の方法。 - 前記ソマトスタチンアゴニストが、D-Phe-シクロ(Cys-Phe-D-Trp-Lys-Thr-Cys)-Thr-ol又はその薬学的に許容可能な塩である、請求項1から3のいずれか一項に記載の方法。
- 前記核酸がヒトGHRをコードする、請求項1から7のいずれか一項に記載の方法。
- 前記核酸が配列番号4又は配列番号5に示されている、請求項8に記載の方法。
- 前記オリゴヌクレオチドが12から50核酸塩基長である、請求項1から9のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドが15から30核酸塩基長である、請求項1から9のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドがDNAオリゴヌクレオチドである、請求項1から11のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドがRNAオリゴヌクレオチドである、請求項1から11のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドが短鎖干渉RNA (siRNA)である、請求項13に記載の方法。
- 前記オリゴヌクレオチドがキメラオリゴヌクレオチドである、請求項1から11のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドが、前記GHRをコードする核酸と少なくとも70%の相補性を有する、請求項1から15のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドが、前記GHRをコードする核酸と少なくとも80%の相補性を有する、請求項1から15のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドが、前記GHRをコードする核酸と少なくとも90%の相補性を有する、請求項1から15のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドが、前記GHRをコードする核酸と少なくとも95%の相補性を有する、請求項1から15のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドが、配列番号6、7、8、9、10、11、12、13、14、15、16、17、18、19、21、22、23、24、25、26、27、29、30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、50、51、52、53、54、55、56、57、58、60、61、62、63、64、65、66、68、69、70、71、72、73、74、75、76、78、79、80、又は81の少なくとも8個の連続する核酸塩基部分を含む、請求項1から19のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドが、配列番号6、7、8、9、10、11、12、13、14、15、16、17、18、19、21、22、23、24、25、26、27、29、30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、50、51、52、53、54、55、56、57、58、60、61、62、63、64、65、66、68、69、70、71、72、73、74、75、76、78、79、80、又は81の核酸塩基配列からなる、請求項1から19のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドが、配列番号6の核酸塩基配列からなる、請求項21に記載の方法。
- 前記オリゴヌクレオチドが、成長ホルモン受容体をコードする領域と特異的にハイブリダイズし、前記領域が、翻訳開始コドン、終止コドン、コード領域、5'非翻訳領域、3'非翻訳領域、イントロン:エキソン接合部又はエキソン:イントロン接合部を含む、請求項1から22のいずれか一項に記載の方法。
- 前記領域が、配列番号84〜154から選択される配列の少なくとも8個の連続する核酸塩基部分を含む、請求項23に記載の方法。
- 前記オリゴヌクレオチドが、配列番号4のヌクレオチド260〜339、332〜351及び344〜423からなる群から選択される、配列番号4の領域に相補的な少なくとも8個の連続する核酸塩基部分を含む、請求項8から19のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドが、GHR及び/又は成長ホルモン結合タンパク質(GHBP)の発現を少なくとも15%阻害する、請求項1から25のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドが、少なくとも1つの修飾ヌクレオシド間結合、糖部分、又は核酸塩基を含む、請求項1から26のいずれか一項に記載の方法。
- 前記オリゴヌクレオチドが、少なくとも1つの2'-O-メトキシエチル糖部分を含む、請求項27に記載の方法。
- 前記オリゴヌクレオチドが、少なくとも1つのホスホロチオエートヌクレオシド間結合を含む、請求項27に記載の方法。
- 前記オリゴヌクレオチドが、少なくとも1つの5-メチルシトシンを含む、請求項27に記載の方法。
- 前記オリゴヌクレオチドが20個の連結ヌクレオシドからなり、前記オリゴヌクレオチドが配列番号6の核酸塩基からなり、前記オリゴヌクレオチドが、10デオキシヌクレオチド領域からなり、前記10デオキシヌクレオチド領域の5'末端及び3'末端の両方に5個の2'-O-(2-メトキシエチル)ヌクレオチドを有し、前記オリゴヌクレオチド中の各ヌクレオシド間結合がホスホロチオエート結合であり、前記オリゴヌクレオチド中の各シトシンが5-メチルシトシンである、請求項27に記載の方法。
- インスリン様成長因子I(IGF-I)のレベルの増加に起因及び/又は関連する疾患を治療又は予防する医薬品の製造における、ソマトスタチンアゴニスト、及び成長ホルモン受容体(GHR)をコードする核酸を標的とする8から80核酸塩基長のオリゴヌクレオチドの使用。
- 前記疾患が、先端巨大症、巨人症、糖尿病性網膜症、糖尿病性腎症、又は前立腺癌、骨髄腫、肺癌、乳癌、若しくは結腸癌などのIGF-I陽性癌である、請求項32に記載の使用。
- 対象におけるインスリン様成長因子I(IGF-I)のレベルを低減する医薬品の製造における、ソマトスタチンアゴニスト、及び成長ホルモン受容体(GHR)をコードする核酸を標的とする8から80核酸塩基長のオリゴヌクレオチドの使用。
- 前記ソマトスタチンアゴニストが請求項4から7に記載の特徴のいずれか1つを更に特徴とし、前記GHRが請求項8又は9に記載の特徴のいずれか1つを更に特徴とし、及び/又は前記オリゴヌクレオチドが請求項10から31に記載の特徴のいずれか1つを更に特徴とする、請求項32から34のいずれか一項に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361834856P | 2013-06-13 | 2013-06-13 | |
US61/834,856 | 2013-06-13 | ||
PCT/AU2014/000613 WO2014197938A1 (en) | 2013-06-13 | 2014-06-13 | Combination therapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019125334A Division JP2019178167A (ja) | 2013-06-13 | 2019-07-04 | 併用療法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016521726A true JP2016521726A (ja) | 2016-07-25 |
JP6869720B2 JP6869720B2 (ja) | 2021-05-12 |
Family
ID=52021495
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016518801A Active JP6869720B2 (ja) | 2013-06-13 | 2014-06-13 | 併用療法 |
JP2019125334A Pending JP2019178167A (ja) | 2013-06-13 | 2019-07-04 | 併用療法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019125334A Pending JP2019178167A (ja) | 2013-06-13 | 2019-07-04 | 併用療法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20160129089A1 (ja) |
EP (1) | EP3007704B1 (ja) |
JP (2) | JP6869720B2 (ja) |
AU (1) | AU2014280847B2 (ja) |
CA (1) | CA2918787A1 (ja) |
DK (1) | DK3007704T3 (ja) |
ES (1) | ES2862125T3 (ja) |
WO (1) | WO2014197938A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019178167A (ja) * | 2013-06-13 | 2019-10-17 | アンチセンス セラピューティクス リミテッド | 併用療法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
WO2017172356A1 (en) * | 2016-03-30 | 2017-10-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting insulin-like growth factor binding protein, acid labile subunit (igfals) and methods of use thereof |
CN114515339B (zh) * | 2022-01-25 | 2023-07-18 | 深圳深创生物药业有限公司 | 针对生长抑素受体的多肽偶联药物及其应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04504723A (ja) * | 1989-04-26 | 1992-08-20 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | 線状ソマトスタチン類似体 |
JPH05506254A (ja) * | 1991-02-08 | 1993-09-16 | バイオメジャー,インコーポレイテッド | 良性および悪性増殖性皮膚病の治療方法 |
JP2004531520A (ja) * | 2001-04-09 | 2004-10-14 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | ソマトスタチンアゴニスト |
JP2007524373A (ja) * | 2003-02-28 | 2007-08-30 | アイシス ファーマシューティカルズ, インコーポレーテッド | 成長ホルモン受容体の発現およびインスリン様成長因子の発現のモジュレーション |
JP2008535882A (ja) * | 2005-04-13 | 2008-09-04 | イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム | 治療法 |
JP2009539803A (ja) * | 2006-06-08 | 2009-11-19 | ノバルティス アクチエンゲゼルシャフト | ソマトスタチン−アナログとドーパミン−または成長ホルモン受容体アンタゴニストの組合せ剤 |
JP2010529982A (ja) * | 2007-06-15 | 2010-09-02 | カムルス エービー | ペプチド徐放性製剤 |
JP2011505345A (ja) * | 2007-12-03 | 2011-02-24 | イタルファルマコ ソシエタ ペル アチオニ | 新規な非選択的ソマトスタチン類似体 |
JP2011527705A (ja) * | 2008-07-11 | 2011-11-04 | エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド. | オクトレオチドの乾燥処方物の送達 |
JP2012512148A (ja) * | 2008-12-15 | 2012-05-31 | ノバルティス アーゲー | ナノ粒子組成物 |
Family Cites Families (214)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4291022A (en) | 1975-03-11 | 1981-09-22 | Sandoz Ltd. | Organic compounds |
LU78191A1 (de) | 1977-09-28 | 1979-05-25 | Ciba Geigy Ag | Verfahren zur herstellung von neuen cyclopeptiden |
US4316890A (en) | 1979-03-16 | 1982-02-23 | Ciba-Geigy Corporation | Peptides and processes for the manufacture thereof |
US4328214A (en) | 1979-07-04 | 1982-05-04 | Ciba-Geigy Corporation | Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture |
DE2935974A1 (de) | 1979-09-06 | 1981-04-09 | Hoechst Ag, 6000 Frankfurt | Disazoverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
DE3062075D1 (en) | 1979-11-27 | 1983-03-24 | Sandoz Ag | Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use |
US4369179A (en) | 1979-12-14 | 1983-01-18 | Ciba-Geigy Corporation | Acylpeptides |
US4358439A (en) | 1979-12-21 | 1982-11-09 | Ciba-Geigy Corporation | Cyclooctapeptides |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
DK81082A (da) | 1981-03-06 | 1982-09-07 | Sandoz Ag | Fremgangsmaade til fremstilling af polypeptider |
US4360516A (en) | 1981-04-13 | 1982-11-23 | Merck & Co., Inc. | Modified D-retro cyclic hexapeptide somatostatin analogs |
US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
ATE14226T1 (de) | 1981-12-24 | 1985-07-15 | Ciba Geigy Ag | Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung. |
US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4824941A (en) | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
US4486415A (en) | 1983-08-15 | 1984-12-04 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
US4485101A (en) | 1983-10-11 | 1984-11-27 | Administrators Of The Tulane Educational Fund | Peptides |
US4522813A (en) | 1983-10-27 | 1985-06-11 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US4725577A (en) | 1985-04-25 | 1988-02-16 | Administrators Of The Tulane Educational Fund | Biologically active lysine containing octapeptides |
US4650787A (en) | 1985-04-25 | 1987-03-17 | Schally Andrew Victor | Biologically active octapeptides |
US4585755A (en) | 1985-04-29 | 1986-04-29 | Merck & Co., Inc. | Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents |
US4762779A (en) | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
US4904642A (en) | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
JPS638396A (ja) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
EP0260032B1 (en) | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers |
NL194729C (nl) | 1986-10-13 | 2003-01-07 | Novartis Ag | Werkwijze voor de bereiding van peptidealcoholen via vaste fase. |
US4871717A (en) | 1987-01-07 | 1989-10-03 | Administrators Of The Tulane Educational Fund | Peptides |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
JP2828642B2 (ja) | 1987-06-24 | 1998-11-25 | ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン | ヌクレオシド誘導体 |
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
ATE151467T1 (de) | 1987-11-30 | 1997-04-15 | Univ Iowa Res Found | Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene |
EP0329295A1 (en) | 1988-02-01 | 1989-08-23 | The Upjohn Company | Renin inhibiting peptides with polar end groups |
US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
WO1989009221A1 (en) | 1988-03-25 | 1989-10-05 | University Of Virginia Alumni Patents Foundation | Oligonucleotide n-alkylphosphoramidates |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
ZA895838B (en) | 1988-08-18 | 1991-03-27 | Syntex Inc | Pharmaceutical compounds |
US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5227170A (en) | 1989-06-22 | 1993-07-13 | Vestar, Inc. | Encapsulation process |
US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
US5527528A (en) | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5721218A (en) | 1989-10-23 | 1998-02-24 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
AU658562B2 (en) | 1989-10-24 | 1995-04-27 | Isis Pharmaceuticals, Inc. | 2' modified oligonucleotides |
US5292873A (en) | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
ES2091907T3 (es) | 1989-12-08 | 1996-11-16 | Univ Tulane | Analogos octapeptidos de somatostina con una threonina en la sexta posicion. |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
AU7579991A (en) | 1990-02-20 | 1991-09-18 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
ATE167523T1 (de) | 1990-05-11 | 1998-07-15 | Microprobe Corp | Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
CA2088258C (en) | 1990-07-27 | 2004-09-14 | Phillip Dan Cook | Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression |
US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
ATE131827T1 (de) | 1990-08-03 | 1996-01-15 | Sterling Winthrop Inc | Verbindungen und verfahren zur unterdrückung der genexpression |
US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
EP0549686A4 (en) | 1990-09-20 | 1995-01-18 | Gilead Sciences Inc | Modified internucleoside linkages |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
DE69132510T2 (de) | 1990-11-08 | 2001-05-03 | Hybridon Inc | Verbindung von mehrfachreportergruppen auf synthetischen oligonukleotiden |
US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
JP3220180B2 (ja) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
EP0538194B1 (de) | 1991-10-17 | 1997-06-04 | Novartis AG | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
DE637965T1 (de) | 1991-11-26 | 1995-12-14 | Gilead Sciences Inc | Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen. |
US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
US5595726A (en) | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
WO1994004752A1 (en) | 1992-08-20 | 1994-03-03 | Industrial Progress, Inc. | Acid-to-alkaline papermaking process |
US5583020A (en) | 1992-11-24 | 1996-12-10 | Ribozyme Pharmaceuticals, Inc. | Permeability enhancers for negatively charged polynucleotides |
US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
ATE236655T1 (de) | 1993-01-06 | 2003-04-15 | Kinerton Ltd | Ionische molekularkonjugate von bioabbaubaren polyestern und bioaktiven polypeptiden |
JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
JPH08508492A (ja) | 1993-03-30 | 1996-09-10 | スターリング ウィンスロップ インコーポレイティド | 非環式ヌクレオシド類似体及びそれらを含むオリゴヌクレオチド配列 |
HU9501974D0 (en) | 1993-03-31 | 1995-09-28 | Sterling Winthrop Inc | Oligonucleotides with amide linkages replacing phosphodiester linkages |
DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
US5462854A (en) | 1993-04-19 | 1995-10-31 | Beckman Instruments, Inc. | Inverse linkage oligonucleotides for chemical and enzymatic processes |
FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
US5534259A (en) | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
EP0733059B1 (en) | 1993-12-09 | 2000-09-13 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US5646269A (en) | 1994-04-28 | 1997-07-08 | Gilead Sciences, Inc. | Method for oligonucleotide analog synthesis |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US5591721A (en) | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
EP0981363B1 (en) * | 1997-05-13 | 2003-07-30 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Somatostatin agonists for decreasing body weight |
AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
MX349009B (es) * | 2001-01-05 | 2017-07-06 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina. |
KR101399911B1 (ko) * | 2005-03-11 | 2014-06-19 | 엔도 파마슈티컬즈, 솔루션스 아이엔씨. | 옥트레오타이드의 방출 조절형 제형 |
GB0602639D0 (en) * | 2006-02-09 | 2006-03-22 | Novartis Ag | Organic compounds |
WO2013080784A1 (ja) | 2011-11-30 | 2013-06-06 | シャープ株式会社 | メモリ回路とその駆動方法、及び、これを用いた不揮発性記憶装置、並びに、液晶表示装置 |
CA2863499C (en) * | 2012-02-03 | 2022-06-21 | George Tachas | Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor |
DK3007704T3 (da) * | 2013-06-13 | 2021-03-29 | Antisense Therapeutics Ltd | Kombinationsterapi til akromegali |
-
2014
- 2014-06-13 DK DK14810926.7T patent/DK3007704T3/da active
- 2014-06-13 JP JP2016518801A patent/JP6869720B2/ja active Active
- 2014-06-13 WO PCT/AU2014/000613 patent/WO2014197938A1/en active Application Filing
- 2014-06-13 EP EP14810926.7A patent/EP3007704B1/en active Active
- 2014-06-13 AU AU2014280847A patent/AU2014280847B2/en active Active
- 2014-06-13 ES ES14810926T patent/ES2862125T3/es active Active
- 2014-06-13 CA CA2918787A patent/CA2918787A1/en active Pending
- 2014-06-13 US US14/897,896 patent/US20160129089A1/en not_active Abandoned
-
2019
- 2019-07-04 JP JP2019125334A patent/JP2019178167A/ja active Pending
-
2021
- 2021-11-01 US US17/516,543 patent/US20220047679A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04504723A (ja) * | 1989-04-26 | 1992-08-20 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | 線状ソマトスタチン類似体 |
JPH05506254A (ja) * | 1991-02-08 | 1993-09-16 | バイオメジャー,インコーポレイテッド | 良性および悪性増殖性皮膚病の治療方法 |
JP2004531520A (ja) * | 2001-04-09 | 2004-10-14 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | ソマトスタチンアゴニスト |
JP2007524373A (ja) * | 2003-02-28 | 2007-08-30 | アイシス ファーマシューティカルズ, インコーポレーテッド | 成長ホルモン受容体の発現およびインスリン様成長因子の発現のモジュレーション |
JP2008535882A (ja) * | 2005-04-13 | 2008-09-04 | イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム | 治療法 |
JP2009539803A (ja) * | 2006-06-08 | 2009-11-19 | ノバルティス アクチエンゲゼルシャフト | ソマトスタチン−アナログとドーパミン−または成長ホルモン受容体アンタゴニストの組合せ剤 |
JP2010529982A (ja) * | 2007-06-15 | 2010-09-02 | カムルス エービー | ペプチド徐放性製剤 |
JP2011505345A (ja) * | 2007-12-03 | 2011-02-24 | イタルファルマコ ソシエタ ペル アチオニ | 新規な非選択的ソマトスタチン類似体 |
JP2011527705A (ja) * | 2008-07-11 | 2011-11-04 | エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド. | オクトレオチドの乾燥処方物の送達 |
JP2012512148A (ja) * | 2008-12-15 | 2012-05-31 | ノバルティス アーゲー | ナノ粒子組成物 |
Non-Patent Citations (1)
Title |
---|
国際商標公報, JPN6019036075, 11 August 2011 (2011-08-11), pages 1057330, ISSN: 0004117657 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019178167A (ja) * | 2013-06-13 | 2019-10-17 | アンチセンス セラピューティクス リミテッド | 併用療法 |
Also Published As
Publication number | Publication date |
---|---|
US20160129089A1 (en) | 2016-05-12 |
JP2019178167A (ja) | 2019-10-17 |
CA2918787A1 (en) | 2014-12-18 |
WO2014197938A1 (en) | 2014-12-18 |
JP6869720B2 (ja) | 2021-05-12 |
AU2014280847A1 (en) | 2016-02-04 |
EP3007704A1 (en) | 2016-04-20 |
EP3007704A4 (en) | 2017-03-15 |
DK3007704T3 (da) | 2021-03-29 |
EP3007704B1 (en) | 2021-01-06 |
ES2862125T3 (es) | 2021-10-07 |
AU2014280847B2 (en) | 2019-07-04 |
NZ715825A (en) | 2021-08-27 |
US20220047679A1 (en) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220047679A1 (en) | Combination therapy | |
US8039444B2 (en) | Antisense permeation enhancers | |
KR101697396B1 (ko) | 결합 조직 성장 인자(ctgf)를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법 | |
BR112019012664A2 (pt) | conjugados de oligômero de salto de éxon para distrofia muscular | |
TW201828996A (zh) | 用於肌肉萎縮症之外顯子跳躍寡聚物結合物 | |
BR112019012651A2 (pt) | conjugados de oligômero de salto de éxon para distrofia muscular | |
JP2011527568A (ja) | 補体アンタゴニストおよびその使用 | |
US9821034B2 (en) | Combination therapy | |
CN112384222B (zh) | 用于肌营养不良的外显子跳跃寡聚物缀合物 | |
US9205102B2 (en) | Method for treatment of castration-resistant prostate cancer | |
EP3787639A1 (en) | Therapeutic uses and methods | |
JP2021526807A (ja) | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170607 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180305 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180319 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180919 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190304 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190704 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20190704 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20190722 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190822 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20190826 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190822 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190920 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20190930 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200107 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20201019 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20201109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210125 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20210208 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20210315 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20210315 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210414 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6869720 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |